According to the director of the National Cancer Institute, an important challenge for cancer research now is modernizing the clinical trial infrastructure. Targeted therapies are changing how clinical trials are conducted, with a shift towards molecularly defined trials, which are more complicated to administer and require next generation sequencing to screen patients for enrollment with narrowly defined inclusion criteria. (BIOPHARMADIVE)